Illumimedical Inc. Completes Series A Funding Round, Raising a Total of 550 Million JPY

Illumimedical Inc. (Location: Nagoya City, Aichi Prefecture), which aims to innovate medical technology using light, has completed its 3rd close, following the 1st close of its Series A round announced in October 2025 and the 2nd close announced in January 2026. The total amount of funding raised in Series A is 550 million JPY. This marks the final close of Series A.

Participants in the Series A 3rd Close:
■ NEX-T Tokai Innovation Fund (jointly operated by Prime Partners/Tokai Tokyo Securities)
■ Meigin Venture Fund No. 1 (operated by Nagoya Capital Partners)
■ Hokkoku Bank (proprietary loan)
■ Japan Finance Corporation (subordinated loan)

The Series A funds will be used for the following:

・Promotion of product development and transfer of developed products to mass production factories
Establishment of a stable supply system for devices that ensure quality and safety for clinical trials.

・Execution of global regulatory and insurance strategies
Formation of alliances with overseas companies and execution of global regulatory and insurance strategies aimed at obtaining global approval in preparation for international joint clinical trials with global pharmaceutical companies.

・Expansion of treatment and diagnostic pipelines
Expansion of pipelines through new alliances with pharmaceutical companies, etc., applying light therapy technology, and business development/research and development aimed at adapting to new disease areas (neurological diseases).

・Securing core talent and strengthening organizational structure
Actively recruiting specialized personnel in medical device development, regulatory affairs, and business development, and establishing a system for global expansion.

Comment from Representative Director Toshihiko Tsukamoto:

"I am truly delighted to have successfully completed the Series A funding round. I extend my heartfelt gratitude to all stakeholders who participated in the 3rd close. The expectations for light-based medical technology have grown even greater compared to about three years ago when our business started. Our entire team will further advance development, aiming for the clinical application of light therapy technology that contributes to extending patients' healthy lifespans by utilizing our technology in various disease areas."

■ About Illumimedical Inc.

Centered on its unique technology "ET-BLIT®" which irradiates light from within blood vessels, the company is developing new treatment approaches for intractable diseases such as cancer and neurological disorders. This funding will accelerate product development and strengthen the business foundation for social implementation.

Representative: Representative Director Toshihiko Tsukamoto
Established: February 2023
Location: Creation Core Nagoya 207, 4-201 Sakurazaka, Moriyama-ku, Nagoya City, Aichi Prefecture 463-0018
URL: https://illumimedical.com/

(Contact for this matter and collaboration with our company)
info@illumimedical.com

(Related Press Releases)

・Illumimedical Inc. Completes Series A Round (1st Close), Raising a Total of 340 Million JPY – Strengthening Manufacturing System, Pipeline, and Human Resources Foundation for Social Implementation of Light Therapy Technology –
https://prtimes.jp/main/html/rd/p/000000016.000131096.html

・Illumimedical Inc. Completes Series A Round (2nd Close), Raising a Total of 410 Million JPY in Series A
https://prtimes.jp/main/html/rd/p/000000020.000131096.html